Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot study.
Identifieur interne : 000581 ( 2020/Analysis ); précédent : 000580; suivant : 000582Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot study.
Auteurs : Atsushi Noguchi [Japon] ; Shinsuke Yasuda [Japon] ; Ryo Hisada [Japon] ; Masaru Kato [Japon] ; Kenji Oku [Japon] ; Toshiyuki Bohgaki [Japon] ; Miho Suzuki [Japon] ; Yoshihiro Matsumoto [Japon] ; Tatsuya Atsumi [Japon]Source :
- Modern rheumatology [ 1439-7609 ] ; 2020.
Abstract
Objectives: To analyze the effects of tocilizumab on peripheral B-cell subpopulation and its ability to produce anti-cyclic citrullinated peptide (CCP) antibody in patients with rheumatoid arthritis (RA).Methods: Thirteen consecutive RA patients initiated with tocilizumab were enrolled in our prospective study. Anti-CCP antibody titers and clinical parameters were evaluated during treatment. Peripheral blood B-cell subsets were analyzed using flow cytometry according to the Human Immunology Project.Results: Disease activity was significantly improved and anti-CCP antibody titers significantly decreased at week 24 compared to baseline. The percentages of post-switch memory B cells in CD19+ cells transiently increased at week 12, but there was no significant difference in any of the investigated B-cell subpopulations at week 24 compared to baseline. The ratios of post-switch memory to naïve B cells (post-switch/naïve) correlated negatively with anti-CCP antibody titers regardless of the time-points.Conclusion: Our study indicated that tocilizumab has a potential to reduce anti-CCP antibody production presumably by affecting post-switch/naïve ratio, and that anti-CCP antibody titers reflect B-cell distribution/subpopulation. As anti-CCP antibodies are produced in lymph nodes or ectopic lymphoid structures in synovial tissues, not in circulation, transient increment of post-switch memory B cells after tocilizumab treatment may reflect the altered balance of B-cell distribution between circulation and arthritic joints, resulting in suppressed production of anti-CCP antibody in situ.
DOI: 10.1080/14397595.2019.1583784
PubMed: 30789096
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000489
- to stream PubMed, to step Curation: 000489
- to stream PubMed, to step Checkpoint: 000224
- to stream Ncbi, to step Merge: 001E16
- to stream Ncbi, to step Curation: 001E16
- to stream Ncbi, to step Checkpoint: 001E16
- to stream Main, to step Merge: 000581
- to stream Main, to step Curation: 000581
- to stream Main, to step Exploration: 000581
- to stream 2020, to step Extraction: 000581
Links to Exploration step
pubmed:30789096Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot study.</title><author><name sortKey="Noguchi, Atsushi" sort="Noguchi, Atsushi" uniqKey="Noguchi A" first="Atsushi" last="Noguchi">Atsushi Noguchi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Yasuda, Shinsuke" sort="Yasuda, Shinsuke" uniqKey="Yasuda S" first="Shinsuke" last="Yasuda">Shinsuke Yasuda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Hisada, Ryo" sort="Hisada, Ryo" uniqKey="Hisada R" first="Ryo" last="Hisada">Ryo Hisada</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Kato, Masaru" sort="Kato, Masaru" uniqKey="Kato M" first="Masaru" last="Kato">Masaru Kato</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Oku, Kenji" sort="Oku, Kenji" uniqKey="Oku K" first="Kenji" last="Oku">Kenji Oku</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Bohgaki, Toshiyuki" sort="Bohgaki, Toshiyuki" uniqKey="Bohgaki T" first="Toshiyuki" last="Bohgaki">Toshiyuki Bohgaki</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Suzuki, Miho" sort="Suzuki, Miho" uniqKey="Suzuki M" first="Miho" last="Suzuki">Miho Suzuki</name><affiliation wicri:level="1"><nlm:affiliation>Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba</wicri:regionArea><wicri:noRegion>Gotemba</wicri:noRegion></affiliation></author><author><name sortKey="Matsumoto, Yoshihiro" sort="Matsumoto, Yoshihiro" uniqKey="Matsumoto Y" first="Yoshihiro" last="Matsumoto">Yoshihiro Matsumoto</name><affiliation wicri:level="1"><nlm:affiliation>Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba</wicri:regionArea><wicri:noRegion>Gotemba</wicri:noRegion></affiliation></author><author><name sortKey="Atsumi, Tatsuya" sort="Atsumi, Tatsuya" uniqKey="Atsumi T" first="Tatsuya" last="Atsumi">Tatsuya Atsumi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:30789096</idno><idno type="pmid">30789096</idno><idno type="doi">10.1080/14397595.2019.1583784</idno><idno type="wicri:Area/PubMed/Corpus">000489</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000489</idno><idno type="wicri:Area/PubMed/Curation">000489</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000489</idno><idno type="wicri:Area/PubMed/Checkpoint">000224</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000224</idno><idno type="wicri:Area/Ncbi/Merge">001E16</idno><idno type="wicri:Area/Ncbi/Curation">001E16</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E16</idno><idno type="wicri:Area/Main/Merge">000581</idno><idno type="wicri:Area/Main/Curation">000581</idno><idno type="wicri:Area/Main/Exploration">000581</idno><idno type="wicri:Area/2020/Extraction">000581</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot study.</title><author><name sortKey="Noguchi, Atsushi" sort="Noguchi, Atsushi" uniqKey="Noguchi A" first="Atsushi" last="Noguchi">Atsushi Noguchi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Yasuda, Shinsuke" sort="Yasuda, Shinsuke" uniqKey="Yasuda S" first="Shinsuke" last="Yasuda">Shinsuke Yasuda</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Hisada, Ryo" sort="Hisada, Ryo" uniqKey="Hisada R" first="Ryo" last="Hisada">Ryo Hisada</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Kato, Masaru" sort="Kato, Masaru" uniqKey="Kato M" first="Masaru" last="Kato">Masaru Kato</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Oku, Kenji" sort="Oku, Kenji" uniqKey="Oku K" first="Kenji" last="Oku">Kenji Oku</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Bohgaki, Toshiyuki" sort="Bohgaki, Toshiyuki" uniqKey="Bohgaki T" first="Toshiyuki" last="Bohgaki">Toshiyuki Bohgaki</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author><author><name sortKey="Suzuki, Miho" sort="Suzuki, Miho" uniqKey="Suzuki M" first="Miho" last="Suzuki">Miho Suzuki</name><affiliation wicri:level="1"><nlm:affiliation>Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba</wicri:regionArea><wicri:noRegion>Gotemba</wicri:noRegion></affiliation></author><author><name sortKey="Matsumoto, Yoshihiro" sort="Matsumoto, Yoshihiro" uniqKey="Matsumoto Y" first="Yoshihiro" last="Matsumoto">Yoshihiro Matsumoto</name><affiliation wicri:level="1"><nlm:affiliation>Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba</wicri:regionArea><wicri:noRegion>Gotemba</wicri:noRegion></affiliation></author><author><name sortKey="Atsumi, Tatsuya" sort="Atsumi, Tatsuya" uniqKey="Atsumi T" first="Tatsuya" last="Atsumi">Tatsuya Atsumi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo</wicri:regionArea><wicri:noRegion>Sapporo</wicri:noRegion></affiliation></author></analytic><series><title level="j">Modern rheumatology</title><idno type="eISSN">1439-7609</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Objectives:</b> To analyze the effects of tocilizumab on peripheral B-cell subpopulation and its ability to produce anti-cyclic citrullinated peptide (CCP) antibody in patients with rheumatoid arthritis (RA).<b>Methods:</b> Thirteen consecutive RA patients initiated with tocilizumab were enrolled in our prospective study. Anti-CCP antibody titers and clinical parameters were evaluated during treatment. Peripheral blood B-cell subsets were analyzed using flow cytometry according to the Human Immunology Project.<b>Results:</b> Disease activity was significantly improved and anti-CCP antibody titers significantly decreased at week 24 compared to baseline. The percentages of post-switch memory B cells in CD19+ cells transiently increased at week 12, but there was no significant difference in any of the investigated B-cell subpopulations at week 24 compared to baseline. The ratios of post-switch memory to naïve B cells (post-switch/naïve) correlated negatively with anti-CCP antibody titers regardless of the time-points.<b>Conclusion:</b> Our study indicated that tocilizumab has a potential to reduce anti-CCP antibody production presumably by affecting post-switch/naïve ratio, and that anti-CCP antibody titers reflect B-cell distribution/subpopulation. As anti-CCP antibodies are produced in lymph nodes or ectopic lymphoid structures in synovial tissues, not in circulation, transient increment of post-switch memory B cells after tocilizumab treatment may reflect the altered balance of B-cell distribution between circulation and arthritic joints, resulting in suppressed production of anti-CCP antibody <i>in situ</i>.</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Noguchi, Atsushi" sort="Noguchi, Atsushi" uniqKey="Noguchi A" first="Atsushi" last="Noguchi">Atsushi Noguchi</name></noRegion><name sortKey="Atsumi, Tatsuya" sort="Atsumi, Tatsuya" uniqKey="Atsumi T" first="Tatsuya" last="Atsumi">Tatsuya Atsumi</name><name sortKey="Bohgaki, Toshiyuki" sort="Bohgaki, Toshiyuki" uniqKey="Bohgaki T" first="Toshiyuki" last="Bohgaki">Toshiyuki Bohgaki</name><name sortKey="Hisada, Ryo" sort="Hisada, Ryo" uniqKey="Hisada R" first="Ryo" last="Hisada">Ryo Hisada</name><name sortKey="Kato, Masaru" sort="Kato, Masaru" uniqKey="Kato M" first="Masaru" last="Kato">Masaru Kato</name><name sortKey="Matsumoto, Yoshihiro" sort="Matsumoto, Yoshihiro" uniqKey="Matsumoto Y" first="Yoshihiro" last="Matsumoto">Yoshihiro Matsumoto</name><name sortKey="Oku, Kenji" sort="Oku, Kenji" uniqKey="Oku K" first="Kenji" last="Oku">Kenji Oku</name><name sortKey="Suzuki, Miho" sort="Suzuki, Miho" uniqKey="Suzuki M" first="Miho" last="Suzuki">Miho Suzuki</name><name sortKey="Yasuda, Shinsuke" sort="Yasuda, Shinsuke" uniqKey="Yasuda S" first="Shinsuke" last="Yasuda">Shinsuke Yasuda</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000581 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd -nk 000581 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= 2020
|étape= Analysis
|type= RBID
|clé= pubmed:30789096
|texte= Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/RBID.i -Sk "pubmed:30789096" \
| HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |